Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00527475 · ClinicalTrials.gov registry record · Phase 2
Ranibizumab and Reduced Fluence PDT for AMD
A Phase 2 study, sponsored by Texas Retina Associates.
- Completed
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
NCT00527475 is a Phase 2 study that has completed, run by Texas Retina Associates. The registered enrollment target is 60 participants.
The verdict
NCT00527475, a Phase 2 study, has completed, sponsored by Texas Retina Associates.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
Study Summary
Single agent anti-VEGF therapies such as ranibizumab have shown great promise and have set the standard for visual outcomes in treating wet macular degeneration. However, they need to be administered frequently by intraocular injections with the attendant risk of endophthalmitis, lens damage, retinal detachment, and vitreous hemorrhage. The purpose of this trial is to see if using photodynamic therapy in combination with ranibizumab will decrease the number of treatments with ranibizumab.
Interventions
- DRUG ranibizumab
- DRUG verteporfin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2007-05 |
| Est. Completion | 2010-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00527475
The ClinicalTrials.gov registry entry for NCT00527475 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Texas Retina Associates, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which ranibizumab is the first listed.
NCT00527475 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00527475 about?
NCT00527475 is a clinical study titled "Ranibizumab and Reduced Fluence PDT for AMD". Single agent anti-VEGF therapies such as ranibizumab have shown great promise and have set the standard for visual outcomes in treating wet macular degeneration. However, they need to be administered frequently by intraocular injections with the attendant risk of endophthalmitis, lens damage, retina...
What is the current status of trial NCT00527475?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2007-05. Estimated completion is 2010-01.
What interventions are being tested in trial NCT00527475?
The interventions under investigation include: ranibizumab (DRUG), verteporfin (DRUG).
Who is sponsoring clinical trial NCT00527475?
This trial is sponsored by Texas Retina Associates, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.